Accepted: 23 June 2015/Published online: 14 July 2015© Italian Society of Endocrinology
(SIE) 2015 advanced ACC remains disappointing for limited efficacy and significant toxicity …

Adrenocortical carcinoma (ACC) is not only a rare and heterogeneous disease but also one
of the most aggressive endocrine tumors. Despite significant advances in the last decade, its …

Adrenocortical carcinoma (ACC) is a rare and in most cases steroid hormone-producing
tumor with variable prognosis. The purpose of these guidelines is to provide clinicians with …

Adrenocortical carcinoma is a rare endocrine malignant disease with a generally
unfavorable but heterogeneous prognosis. Although even in advanced stages a subset of …

Introduction: Adrenocortical carcinoma (ACC) is a rare tumor characterized by poor
prognosis in most cases. Moreover, in most cases ACC produces an excess of adrenal …

Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy, and most of the
diagnostic and therapeutic strategies are not fully established according to criteria of …

Context: Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with
incompletely understood pathogenesis and poor prognosis. Patients present with hormone …

Adrenocortical carcinoma (ACC) is reported to be present in 3–10% of the population with
most tumors presenting as benign tumors. Most cases of ACC are a sporadic accumulation …

Surgery by experienced team is the key treatment for localized ACC, whereas currently used
chemotherapy has limited efficacy in advanced ACC. The improved understanding of the …

Adrenocortical carcinoma (ACC) is a devastating tumor for either patients or their families
because of short life expectancy and severe impact on quality of life. Due to the rarity of …